We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 30

China proposes new drug GMPs, significantly raising standards
  • Sidley Austin LLP
  • China
  • October 28 2009

On September 23, the State Food and Drug Administration of China ("SFDA") published a draft of revised drug good manufacturing practices ("GMP") for public comments ("GMP 2009"


China proposes new ADR reporting rule
  • Sidley Austin LLP
  • China
  • July 30 2009

On June 30, the Ministry of Health ("MOH") and the State Food and Drug Administration ("SFDA") of China issued a draft revision of the Rule on Adverse Drug Reaction Reporting and Monitoring (the "Reporting Rule"


Updates on international pricing issues for pharmaceutical and biologic products
  • Sidley Austin LLP
  • China, European Union, France, Germany, United Kingdom, USA
  • May 18 2012

Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies


China issues new rule on medical device advertisements
  • Sidley Austin LLP
  • China
  • June 5 2009

On May 13, the Ministry of Health (MOH), the State Administration of Industry and Commerce (SAIC) and the State Food and Drug Administration (SFDA) of China jointly issued an amended Rule for Review of Medical Device Advertisements (the Rule) and accompanying Standards for Review of Medical Device Advertisements (the Standards), both of which went into effect on May 20


China’s comprehensive health care reform plan: implications for pharmaceutical and device firms
  • Sidley Austin LLP
  • China
  • April 9 2009

On April 6, the State Council of China made public the Guideline on Further Reforming the Health Care System (the Guideline), and on the following day the Action Plan for Health Care System Reform: 2009 - 2011 (the Action Plan


China’s new drug GMP significantly raises drug manufacturing standards
  • Sidley Austin LLP
  • China
  • February 17 2011

On February 12, 2011, after rounds of revisions that took more than 5 years, the Ministry of Health of China ("MOH") published the final version of China's new drug GMP ("GMP 2010"


China drug supply chain and GXP update
  • Sidley Austin LLP
  • China
  • January 4 2012

On December 23, 2011, the State Food and Drug Administration (SFDA) of China published the latest round of proposed revisions to the Drug Good Supply Practice Regulation (Draft GSP) for public comment by January 13, 2012


China issues five-year plan for pharmaceutical and medical device industries
  • Sidley Austin LLP
  • China
  • January 20 2012

On January 19, 2012, the Chinese Ministry of Industry & Information Technology issued the Twelfth Five-Year Plan (2011-2015) for the Development of Pharmaceutical and Medical Device Industries (the Plan


China issues new rules to tackle conflict of interest of healthcare government officials
  • Sidley Austin LLP
  • China
  • January 12 2012

On December 26, the Chinese Ministry of Health (MOH) issued the Rules on Prohibition of Conflict of Interest for Healthcare Officials


Chinese government publishes Vaccine Supply System Development Plan
  • Sidley Austin LLP
  • China
  • January 11 2012

On December 22, the State Council of China published the Vaccine Supply System Development Plan